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Despite substantial declines in mortality following myocardial infarction (MI), subsequent left ventricular re-
modeling (LVRm) remains a signiﬁcant long-term complication. Extracellular small non-coding RNAs (exRNAs)
have been associated with cardiac inﬂammation and ﬁbrosis and we hypothesized that they are associated with
post-MI LVRm phenotypes. RNA sequencing of exRNAs was performed on plasma samples from patients with
“beneﬁcial” (decrease LVESVI ≥ 20%, n= 11) and “adverse” (increase LVESVI ≥ 15%, n= 11) LVRm. Selected dif-
ferentially expressed exRNAswere validated by RT-qPCR (n=331) and analyzed for their associationwith LVRm
determined by cardiac MRI. Principal components of exRNAs were associated with LVRm phenotypes post-MI;
speciﬁcally, LV mass, LV ejection fraction, LV end systolic volume index, and ﬁbrosis. We then investigated the
temporal regulation and cellular origin of exRNAs inmurine and cell models and found that: 1) plasma and tissue
miRNA expressionwas temporally regulated; 2) themajority of themiRNAswere increased acutely in tissue and
at sub-acute or chronic time-points in plasma; 3)miRNA expressionwas cell-speciﬁc; and 4) cardiomyocytes re-
lease a subset of the identiﬁed miRNAs packaged in exosomes into culture media in response to hypoxia/reoxy-
genation. In conclusion, we ﬁnd that plasma exRNAs are temporally regulated and are associated with measures
of post-MI LVRm.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
There have been substantial improvements in acute myocardial in-
farction (MI) care in recent decades, resulting in reduced mortality
rates during the acute post-MI phase. Despite this, post-MI cardiac re-
modeling and the subsequent development of heart failure (HF) re-
mains a key long-term source of morbidity for this patient group
(Ezekowitz et al., 2009). Left ventricular remodeling (LVRm) post-MI
is amultifaceted anddynamic process that is the product of the complex
interplay between infarct size, genetic and epigenetic inﬂuences on cell
biology, and effects of neurohormonal antagonism (Heusch et al., 2014).
Recently, there has also been growing interest in the role of inﬂamma-
tion in post-MI LVRm (Abbate et al., 2015). Early identiﬁcation of path-
ological LVRm is a signiﬁcant clinical challenge in the treatment of post-
MI patients. Natriuretic peptides are the current gold standard bio-
marker for HF; however, a limitation of their use is that levels are typi-
cally only elevated once there is a change in LV function and signiﬁcant
remodeling has already occurred (Talwar et al., 2000). Although there is
an inverse relationship between LV ejection fraction (LVEF) and likeli-
hood of adverse remodeling, many patients with a preserved LVEF
post-MI will still go on to develop adverse remodeling (Abbate et al.,
2015). In fact, the majority of post-MI HF cases in the modern era
occur with preserved LV function and may not be captured by alter-
ations in natriuretic peptides (Wijk et al., 2015).
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Post-MI LVRm consists of distinct phases involving multiple cell
types in the heart including cardiomyocytes, ﬁbroblasts, endothelial
cells, and leukocytes (Burchﬁeld et al., 2013). The acute post-MI phase
is hallmarked by cardiomyocyte death and subsequent recruitment of
inﬂammatory cells to remove dead cells and begin the repair process.
Distinct from this period is a sub-acute phase where the inﬂammatory
response is resolved and ﬁbroblast proliferation and secretion of extra-
cellular matrix proteins leads to the formation of scar. Chronically, con-
tinuation of these processes and the global impact of molecular changes
on cardiac function leads to what is termed “beneﬁcial” or “adverse”
LVRm (Burchﬁeld et al., 2013). Differences in cellular response to
events, timing of the resolution of inﬂammatory response, and the de-
gree of ﬁbrosis all contribute to driving LVRm down either beneﬁcial
or adverse paths (Anzai, 2013). Themolecularmechanisms andmarkers
of these stages and processes have not been fully characterized. An in-
creased understanding of the molecular architecture of post-MI remod-
eling offers the opportunity to identify potential early markers of
adverse LVRm and therapeutic targets to prevent the development of
post-MI HF.
The past decade has seen the phenomenon of the non-coding RNA
revolution, where previously disregarded RNA species have been
rediscovered as critical regulators of physiological and pathological pro-
cesses (Cech and Steitz, 2014). Small non-coding RNAs are short regula-
tory transcripts (b200 nt) including the extensively studied microRNAs
(miRNA) (Rajan et al., 2014), and more recently re-discovered piwi-
interacting RNA (piRNA) (Rajan et al., 2014), small nucleolar RNA
(snoRNA) (Stepanov et al., 2015), tRNA fragments (Cozen et al., 2015),
and yRNA fragments (Cambier et al., 2017). These RNA species can affect
the expression of genes and pathways important in cardiovascular dis-
eases (CVD) including myocardial ﬁbrosis (Thum, 2014), coronary ath-
erosclerosis (Aryal et al., 2014), and cardiac arrhythmias (Kim, 2013).
Importantly, they are stably expressed in the circulation (extracellular
RNA; exRNA) as well as in tissue, leading to potential utility as diagnos-
tic and prognostic biomarkers of disease. Signiﬁcant work has been di-
rected to the study of plasma exRNAs in acute coronary syndrome and
in coronary artery disease. However, the majority of studies have been
focused on candidate plasma miRNAs (Jancovicova et al., 2017, Zile
et al., 2011), rather than using an unbiased discovery approach. Hence
few studies have investigated the association of other circulating non-
coding RNAs with MI or LVRm in humans and the only other reported
non-coding RNA species to date are long non-coding RNA (Li et al.,
2017, Gao et al., 2017b, Piccoli et al., 2017).
In this study, we examine the landscape of exRNAs in human circu-
lation by RNA sequencing (RNAseq) to determine whether changes in
plasma exRNAs post-MI are associated with LVRm. Furthermore, the
cellular origin and temporal regulation of candidate exRNAs is exam-
ined in animal and cell models of cardiac ischemia. This is intended as
an exploratory study to identify exRNA signatures associated with
LVRm, and increase our understanding of the molecular architecture
and biology of LVRm. Future studies in expanded cohorts for validation
are important next steps for the development of these exRNA signatures
as clinical biomarkers for post-MI LVRm.
2. Materials and Methods
2.1. Patient Population (OMEGA-REMODEL Trial)
The Omega-3 Acid Ethyl Esters on LV Remodeling After Acute MI
(OMEGA-REMODEL; clinicaltrials.gov identiﬁer NCT00729430) trial
was a prospective, multicenter, double-blind, placebo-controlled trial
testing the effect of omega-3 fatty acid supplementation (4 g/day) for
6 months after acute MI on adverse LVRm by cardiac magnetic reso-
nance imaging (CMR, full study report in Heydari et al., 2016). The Insti-
tutional Review Boards of the respective institutions approved all
protocols involving human patients and all participants provided writ-
ten informed consent. This study conformed to standards indicated by
the Declaration of Helsinki. Venous blood from OMEGA-REMODEL was
collected in EDTA vacutainers at the time of baseline CMR imaging
(2–4weeks post-MI), centrifuged at 2000 ×g for 10min for plasma sep-
aration, and immediately stored at−80 °C. CMR phenotyping (detailed
in previous work by our group; (Heydari et al., 2016)) included LV end-
systolic volume index (LVESVI), LVEF, myocardial mass, infarct size, and
extracellular volume fraction (ECV; a validated surrogate of myocardial
interstitial expansion (Haaf et al., 2016)). Of the 331 subjects in the
overall study, 238 underwent post-treatment follow-up CMR for serial
comparison for LV remodeling. Baseline characteristics were compared
via chi-squared (categorical) or Wilcoxon tests (continuous).
2.2. Identiﬁcation of Patients with Favorable and Adverse LVRm and their
Respective Propensity-Matched Controls
Reduction of LVESVI during the convalescent phase after MI has
remained the most robust risk marker across early (White et al., 1987,
Migrino et al., 1997) and recent clinical trials (St John Sutton et al.,
2017, Doughty et al., 2004). Consistent with other acute MI clinical tri-
als, therewas a high proportion of favorable structural LVRm in patients
of the randomized OMEGA-REMODEL study.We therefore deﬁned ben-
eﬁcial LVRm as N20% reduction of indexed LVESV (LVRmfav = 1) given
its high speciﬁcity towards favorable post-MI HF prognosis to be consis-
tent with the published literature (St John Sutton et al., 2017). Patients
with an expansion of indexed LVESV of N15% were deﬁned as adverse
remodelers (LVRmfav = 0). A logistic regression was then performed
to identify the strongest propensity-matched patient pairs based on pa-
tient age, gender, baseline LVEF, baseline infarct size by late gadolinium
enhancement, and a history of diabetes. A validated propensity score-
based 5 to 1 greedymatching algorithmwasused tominimizematching
bias (http://www2.sas.com/proceedings/sugi26/p214-26.pdf). The 11
best-matched patient pairs were then chosen.
In addition to patients with favorable and adverse LVRm, patients
with adverse electrical remodeling (n = 10) were identiﬁed and
matched to patients without adverse electrical remodeling (n = 10)
as described above. Adverse electrical remodeling was deﬁned as sud-
den cardiac arrest or the detection of ambient ventricular arrhythmia
on clinical follow-up.
2.3. RNASeq of Plasma Samples
RNAseq was performed on the 11 best-matched patient pairs with
beneﬁcial and adverse LVRm and on the 10 best-matched patients
with and without adverse electrical remodeling. RNA was extracted
from 1mL plasma and libraries constructed according to our previously
published methods (Danielson et al., 2017). Brieﬂy, plasma RNA was
isolated using the miRCURY RNA Isolation kit for Bioﬂuids (Exiqon)
with modiﬁed protocol and libraries were constructed and ampliﬁed
from approximately 10 ng RNA using the NEBNext small RNA library
prep set for Illumina (NEB). Size selection of libraries was performed
by gel electrophoresis on a 10% Novex TBE gel with excision of the
140 to 160 nucleotide bands (corresponding to 21–40 nucleotide RNA
fragments). Libraries were diluted to a ﬁnal concentration of 2 nM,
pooled, and sequenced on an Illumina HiSeq 2000 for single read
50 cycles at the Center for Cancer Computational Biology at Dana-
Farber Cancer Institute.
Healthy controls were used from a different study in our laboratory
and were prepared using an alternative method (Shah et al., 2017).
Brieﬂy, plasma exRNA from 26 subjects was isolated using a modiﬁed
mirVana PARIS protocol (AM1556; Life Technologies) with sequential
phenol–chloroform extractions (Burgos et al., 2013). RNA was concen-
trated using the Zymo RNA Clean & Concentrator kit (Zymo Research)
and libraries were prepared using the NEXTﬂex Small RNA Sequencing
Kit v2 by Bioo-Scientiﬁc. Pools of 15 samples were created, denatured
and clustered on either a single read Illumina V3 ﬂowcell (GD-401-
3001; Illumina) or a single read rapid Illumina V2 ﬂowcell (GD-402-
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4002; Illumina). The ﬂowcells were run on the Illumina HiSeq 2500
(Illumina) for 50 cycles with a 7 cycle indexing read.
2.4. Next Generation Sequence Analysis
The BCL ﬁles were de-multiplexed using CASAVA v1.82, and the
adaptor sequences within the read sequences were trimmed by FastX-
Toolkit (http://hannonlab.cshl.edu/fastx_toolkit). The processed se-
quences were ﬁltered for small RNAs N16 nucleotides in length. The se-
quenceswere then aligned, quantiﬁed, and annotated using sRNABench
1.0 pipeline (Barturen et al., 2014). Brieﬂy, thepipeline implemented hi-
erarchical sequence mapping strategy that ﬁrst mapped and removed
spike-in library, contaminants, and rRNA. Next, RNA species were se-
quentially mapped to known mature miRNA, tRNA, snoRNA, piRNA,
and yRNA on the human genome sequence (hg19) using Bowtie2
(Langmead et al., 2009) with parameters that allow for 1 mismatch in
seed alignment (-N 1), try two set of seeds (-R 2), and set the length
of seed substrings to be 16 (-L 16). Mapped small RNA species were
quantiﬁed to read counts and normalized to reads per kilobase per mil-
lion reads mapped (RPKM). Differential expression analysis was per-
formed using edgeR (Robinson et al., 2010) from Bioconductor
(Gentleman et al., 2004) for all contrasts. The p-values were adjusted
for multiple-test correction using False Discovery Rate (FDR)
(Benjamini and Hochberg, 1995). All fastq ﬁles have been deposited
into the exRNA Atlas (http://exrna.org/resources/data/), accession
number EXR-SADAS1UJ0CzW-AN as part of Extracellular RNA Commu-
nication Consortium data sharing, and is widely available. For all reads
mapped to the human miRNAs, isomers of miRNAs (isomiRs) were
identiﬁed with respect to the canonical miRNA sequence as found in
miRBase v21. All isomiRs depicted in this Fig. S4C are length variations
– extensions (titled “ext”) or shortening (titled “trimmed”) and se-
quence variations (“Unmatched”). The 5′ or 3′ refers to the end of the
miRNAwhere the sequence length alteration is observed. These isomiRs
are isoforms (both sequence and length variations) based upon the ca-
nonical miRNA deﬁned by miRBase v21.
2.5. High Throughput RT-qPCR
RNA was extracted from plasma (331 patients, OMEGA-REMODEL
trial) usingmiRCURY RNA Isolation Kit – Bioﬂuids (Exiqon) and reverse
transcribed using miScript II RT Kit (Qiagen, Fredrick, MD, USA). cDNA
samples were pre-ampliﬁed with miScript Microﬂuidics PreAMP Kit
(Qiagen, Fredrick,MD,USA) and RT-qPCRmiRNAproﬁling analyses per-
formed on the BioMark System (Fluidigm Corp. South San Francisco,
CA) using miScript miRNA Assays (Qiagen, Fredrick, MD, USA) and Dy-
namic Array 96.96 (Fluidigm Corp. South San Francisco, CA). A Ct value
of 23 was set as the cut-off point for detectable miRNA species. Mea-
surement of RNAs on the Fluidigm platform has previously been exten-
sively validated against conventional RT-qPCR (Jang et al., 2011). The
qPCR raw data has been deposited in GEO (accession number:
GSE112690).
2.6. Principal Components Analysis (PCA)
We utilized PCA, an unsupervised learning technique that statisti-
cally groups correlated miRNAs together into components, for analysis
of both RNAseq data and RT-qPCR validation data. For analysis of differ-
ences in miRNA proﬁles between post-MI patients and healthy controls
(RNAseq data), miRNA reads per million (RPM) for all subjects were
computed and entered into PCA after they were mean-centered, stan-
dardized (mean 0, variance 1), and log-transformed; the ﬁrst two prin-
cipal components were plotted for all subjects. For the validation data
(RT-qPCR), miRNA values from high-throughput RT-qPCR were mean-
centered and standardized, and entered into the PCA. Values that were
below-detection limit were treated as “23” in the analysis (the upper
limit the assay, reﬂecting very low plasma RNA expression level).
Varimax rotation was used to determine ﬁnal PC loadings. We included
4 principal components (PCs) based on (1) examination of an eigen-
value scree plot, and (2) inclusion of PCs that explain up to 60% of pop-
ulation variance (61.3% for 4 PCs). PC scores based on loadings and
miRNA expression values were included in linear regression models
for association with CMR measures (see below).
2.7. Ingenuity Pathway Analysis (IPA)
mRNA targets of the miRNAs from PC1, PC2, and PC3 (validation
data) that had a loading N60% were obtained through IPA microRNA
Target Filter. Only thosemRNAs that were experimentally observed tar-
gets of themiRNAs from each PCwere chosen to be included in the core
pathway analysis form IPA.
2.8. Association between exRNAs and LV Remodeling by CMR
We performed serial quantitation of LV volumes (end-diastole and
end-systole), ECV in the non-infarct myocardium as a surrogate mea-
sure of interstitial ﬁbrosis, and infarct size by late gadolinium enhance-
ment (Heydari et al., 2016). A 16-segmental map was used in
quantitation of ECV and infarct size and segments with late gadolinium
enhancement were not included in the measurement of non-infarct
ECV. We estimated linear regression models for several cross-sectional
(at the time of the blood draw, baseline at 2–4 weeks post-MI) and lon-
gitudinal LV phenotypes (changes in LV phenotypes from baseline to
6 months post-MI): (1) LVESVI; (2) LVEF; (3) LV mass index. In addi-
tion, we examined the association of baseline non-infarctmyocardial ﬁ-
brosis by ECV with each PC. Each regression model was speciﬁed with
each of the 3 CMR parameters as the outcome (dependent variable), in-
cluded all 4 PC scores, as well as adjustment for age, sex, race, presence
of diabetes, a binary variable denoting randomization (to omega-3 fatty
acid therapy vs. placebo), and a binary variable representing use of any
LVRmmedication (beta-blockade, angiotensin converting enzyme inhi-
bition, or angiotensin-II receptor blockade). For the exRNAs other than
miRNAs (yRNAs, snoRNAs and piRNAs), linear regression was carried
out for mean centered and standardized Ct values as a function of
changes in LV phenotypes from baseline to 6 months post-MI (LVESVI,
LV Mass, LVEF) after adjustment for all the variables used in the PC re-
gression analysis.
2.9. Animal and Cell Models of Ischemia/Reperfusion and Hypoxia
2.9.1. Murine Model of Ischemia/Reperfusion
Adult wild-type C57BL/6 mice were subjected to ischemia reperfu-
sion (I/R) consisting of 30 min left anterior coronary artery (LAD) liga-
tion followed by reperfusion, as previously described (n = 5; Matsui
et al., 2002). “Sham” surgeries without ligation were performed as a
control (n = 4; Fig. S1). Animals were survived for 24 h, 1 week, or
4 weeks prior to sacriﬁce and blood and heart tissue was collected.
2.9.2. Adult Murine Cell Isolation and Culture
Cell speciﬁc miRNA expression was investigated in cells isolated
from healthy adult wildy type mice. Hearts were collected from mice
to isolate cardiomyocytes and non-cardiomyocytes (Liu et al., 2015),
and primary endothelial cells and ﬁbroblasts were cultured from
mouse hearts of as previously described (Ashida et al., 2011). Isolated
cardiomyocytes, non-cardiomyocytes, and cultured primary endothelial
cells were conﬁrmed by RT-qPCR analysis cell-speciﬁc markers includ-
ing cTnI, CD31, and Col1a1 (Fig. S2).
2.9.3. Cell Model of Hypoxia/Reoxygenation in Neonatal Cells
Neonatal rat ventricular myocytes (NRVMs) were isolated from
1 day postnatal Sprague-Dawley pups (Melman et al., 2015) and sub-
jected to 24 h hypoxia (2% oxygen) followed by 12 h re-oxygenation.
Cells were harvested in lysis buffer (miRVANA PARIS kit) and media
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was collected and sequentially centrifuged at 2000 ×g for 10 min and
3000 ×g for 10 min. All cell experiments were run in duplicate across
at least 3 separate NRVM isolations.
2.9.4. RNA Extraction and RT-qPCR for Animal and Cell Models
RNA from cultured or isolated murine cells and mouse tissue sam-
ples were isolated using TRIzol following the manufactures' protocol.
Plasma samples were “spiked” with 5 pmol/mL exogenous cel-miR-
39-3p and RNA was extracted using the miRCURY RNA Isolation kit for
Bioﬂuids (Exiqon) according to manufacturer's protocol. Extracellular
vesicle (EV) associated RNA was extracted from NRVM culture media
using the exoRNEASY kit (Qiagen) and cellular RNA extracted with the
miRVANA PARIS kit according to manufacturer's protocol (Ambion).
All RNA samples were reverse transcribed by Universal cDNA Synthesis
kit (Exiqon) and RT-qPCR performed for speciﬁc miRNA species using
the LNA-based Exiqon platform.
2.9.5. Statistical Analysis
U6 (mouse tissue and NRVM cells), cel-miR-39-3p (plasma), or hsa-
miR-191-5p (isolated murine cells) was used for RT-qPCR normaliza-
tion; due to a lack of reliable housekeeper genes, culture media EV
miRNAwas normalized to cell number and media volume input. Statis-
tical analysis was performed on ΔCt values using Graphpad Prism soft-
ware. Data from the mouse model was analyzed by one-way ANOVA
with Tukey post-hoc analysis, and cell data by Student's t-test. Addition-
ally, the RT-qPCR ΔCt values for mouse tissue, plasma, and cell data
were exponentiated as 2–1/Ct, scaled, and centered before unsupervised
agglomerative hierarchical clustering with the Manhattan distance
measure and the Ward method of clustering was performed. The clus-
tering results were plotted as a heatmap using a modiﬁed version of
heatmap.2 in R.
3. Results
3.1. exRNAs in Post-MI Patient Population
3.1.1. Baseline Characteristics of the Study Population
Baseline characteristics of the study population are presented in
Table 1. Blood was collected from patients at time of initial CMR
(2–4 weeks post-MI) and 238 underwent post-treatment follow-up
CMR 6 months later (Table 2). The vast majority of patients in our ana-
lytic cohort had beneﬁcial LVRm and preserved LVEF (mean 56.6 ±
7.9%). Histograms of the percent change in LVESV and LVM (Fig. S3)
demonstrate that the majority had little change in these variables and
more importantly, very few had adverse LVRm as seen in the right-tail
of the distribution in these histograms. From this cohort we selected n
= 11 patients with beneﬁcial and n = 11 patients with adverse LVRm
for RNAseq analysis, which were well matched for baseline demo-
graphics and disease severity (Table S1 for description of study subpop-
ulations for sequencing). In addition, n = 10 patients with adverse
electrical remodelingwerematched to n=10 patients without adverse
electrical remodeling for RNAseq analysis. However, follow up clinical
data revealed that only 2 of the 331 patients in this cohort experienced
sudden cardiac death and so differentially expressed RNAs between
these patient groups were not analyzed further. However, sequence
data is available for the adverse electrical remodeling group (exRNA
Atlas accession number: EXR-SADAS1UJ0CzW-AN).
3.1.2. RNAseq and exRNA Diversity
RNAseq was performed on plasma from these 22 patients (n = 11
beneﬁcial and n= 11 adverse LVRm as above). Sequencing quality sta-
tistics shown in Table S2. Top RNA species detected by sequencing in-
cluded miRNA, piRNA, yRNA fragments, tRNA fragments, and snoRNA
(Fig. 1a), and the percentage of reads assigned to each species was not
signiﬁcantly different between the two groups. In this studywe primar-
ily focused onmiRNA, of which 188 different species were expressed in
at least 50% of all samples, with 42 different species expressed across all
samples. To identify miRNA candidates differentially expressed be-
tween beneﬁcial and adverse LVRm, we performed differential expres-
sion analysis between the two subgroups. To focus on miRNAs
ubiquitously abundant in plasma and suitable as biomarker candidates,
we selected miRNA candidates with a fold change in expression of ≥2
(or ≤ 0.5), a nominal p value of ≤0.1, and expression (RPKM N 0) across
≥50% of samples. This yielded 21 miRNA candidates from the discovery
cohort for validation (miR-30a-5p, miR-100-5p, miR-146a-5p, miR-
146b-5p, miR-744-5p, miR-98-5p, miR-194-5p, miR-29b-3p, miR-29c-
3p, miR-378c, miR-378e, miR-381-3p, miR-658, miR-15a-5p, miR-
193b-5p, miR-200a-3p, miR-215-5p, miR-3168, miR-4306, miR-4326,
andmiR-4443). We included 12 additional miRNAs candidates selected
from the literature that had previously reported aberrant expression or
relevance in cardiovascular disease (miR-21-5p (Li et al., 2016), miR-
30d-5p (Melman et al., 2015), miR-1 (Melman et al., 2014), miR-423-
5p (Thum, 2014), miR-150-5p (Devaux et al., 2013), miR-223-3p,
(Zampetaki et al., 2012), miR-29a-3p (Roncarati et al., 2014), miR-
29a-5p (Roncarati et al., 2014), miR-155-5p (Seok et al., 2014), miR-
208b-3p (Lv et al., 2014), miR-208a (Melman et al., 2014), miR-133a-
5p (Sayed et al., 2009), miR-499a-5p (Zaseeva et al., 2016)). A diagram
outlining the analysis approach utilized in this study is shown in Fig. 1b.
To determine how miRNA expression differed between post-MI pa-
tients and healthy controls, this data was compared to RNAseq data
Table 1
Baseline clinical and biochemical characteristics of individuals in the RT-qPCR cohort (N
≤ 331). Values for continuous covariates expressed as mean ± standard deviation; cate-
gorical covariates are expressed as a fraction of the overall cohort.
Variable N Value
Age (years) 331 58.9 ± 10.1
Female, % 331 64 (19%)
White race, % 331 268 (81%)
Diabetes, % 331 86 (26%)
Current or prior smoking, % 331 166 (50%)
Hypertension, % 331 213 (64%)
Hyperlipidemia, % 331 234 (71%)
Prior myocardial infarction, % 331 196 (59%)
Body mass index (kg/m2) 331 29.0 ± 5.4
Systolic blood pressure (mmHg) 329 121 ± 16
Diastolic blood pressure (mmHg) 329 70 ± 10
ST-elevation myocardial infarction, % 331 196 (60%)
Aspirin use 331 325 (98%)
Beta blocker use 331 303 (92%)
Angiotensin converting enzyme inhibitor use 331 244 (74%)
Statin use 331 320 (97%)
Randomized to omega-3 fatty acid, % 331 162 (49%)
Serum total cholesterol, mg/dl 305 138 ± 67
Serum high density lipoprotein, mg/dl 305 37 ± 27
Serum low density lipoprotein, mg/dl 304 80 ± 47
Serum triglycerides, mg/dl 305 121 ± 95
Table 2
Baseline (2–4week) andﬁnal (6month)CMR imaging characteristics. Allmorphologic pa-
rameters are indexed to body surface area, calculated at the time of CMR. The “Δ” (change)
indices are calculated as ﬁnal (6-month) value minus baseline (4-week) value divided by
initial value. Late gadolinium enhancement was measured by the full-width half-maxi-
mum technique.
CMR index Baseline (N ≤ 331) Follow-up (N ≤
238. 72%)
N Mean (or N) N Mean (or N)
LVESVI (ml/m2) 331 39.4 ± 16.5 238 36.8 ± 13.1
LV mass index (g/m2) 319 60.0 ± 14.5 226 57.5 ± 13.0
LV ejection fraction, % 331 53.9 ± 9.4 238 56.6 ± 7.9
RV ejection fraction, % 331 53.3 ± 7.1 239 52.6 ± 7.7
Late gadolinium enhancement, g 327 17.4 ± 17.2 244 14.0 ± 13.9
Average extracellular volume fraction 255 0.34 ± 0.05 192 0.35 ± 0.05
ΔLVESVI – 238 −2 ± 19%
ΔLV mass index – 219 −2 ± 17%
ΔLV ejection fraction – 238 3 ± 12%
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from a cohort of 26 healthy controls (age in years: 44 ± 11.8; female:
38%) (Shah et al., 2017). PC analysis on miRNA expression for these
three groups shows robust separation between healthy controls and
post-MI patients, while the beneﬁcial and adverse LVRm groups
shows a more subtle separation (Fig. S4a). It should be noted that the
post-MI and healthy control cohorts were sequenced using different
preparation kits (NEBNext small RNA library prep set for Illumina and
NEXTﬂex Small RNA Sequencing Kit v2 by Bioo-Scientiﬁc, respectively)
which could inﬂate differences between the two groups due to kit
biases. However, a recent study published by our group has shown
that while RNA expression differences exist between different kits,
this is low compared to biological differences observed (Yeri et al.,
2018).
Identiﬁcation and quantiﬁcation of isomiRs was conducted using an
in-house built analysis pipeline. Several isomiR categories were identi-
ﬁed, including extensions and shortenings at both the 5′ and 3′ ends
of the miRNA and sequence variations (Fig. S4C). However, there were
no signiﬁcant differences in isomiR frequencies between our beneﬁcial
and adverse remodeling groups. Due to this fact, and a lack of under-
standing of the relevance of plasma exRNAs and the absence of univer-
sally agreed upon reliable RT-qPCR methodologies for isomiR analysis
(Magee et al., 2017), further analysis of speciﬁc isomiRs was not con-
ducted in our larger patient cohort.
In addition to miRNA, statistically signiﬁcant differential expression
was detected for 4 annotatedpiRNAs, 1 snoRNA, and differential expres-
sion trending towards signiﬁcance for 1 yRNA fragment (corresponding
to the 5′ fragment of yRNA 1; Fig. S4b). We considered non-miRNA
exRNAs as exploratory given their limited and variable annotation and
unclear function, and thus focused on miRNA candidates for further
analysis. Nonetheless, we did assess the association of these exRNAs
with LVRm phenotypes in the validation cohort.
3.1.3. Association of Candidate exRNAs with Baseline and Serial LV Pheno-
types by CMR
The miRNA candidates selected above were measured in 331 partic-
ipants of the OMEGA-REMODEL study by high-throughput RT-qPCR
(Table S3). Due to the vast majority of these patients exhibiting rela-
tively favorable LVRm, which would result in reduced effect sizes be-
tween the miRNAs and serial LV phenotypes, and to eliminate
collinearity of the miRNAs, we chose to analyze the RT-qPCR data by
PC regression. This allowed us to examine the correlation of PC factors
consisting of distinct sets of miRNA correlated with distinct CMR mea-
sures and biological processes. PCA demonstrated 4 PCs accounting for
61.3% of total variance.We used PC loading, which indicates the amount
of variation explained by a variable, as a measurement of inﬂuence by a
speciﬁc miRNA in a given PC. miRNAs with ≥60% loading in a given PC
and with N60% expression across samples (14 total miRNAs) are
shown in Fig. 2b and Table S4. In linear models for association of PCs
with baseline and follow-up CMR parameters (Table S5), we found sta-
tistically signiﬁcant associations between several PCs and myocardial
structure/function (Fig. 2a–b): PC1 vs. change in LV Mass; PC2 vs.
LVESVI, LVEF, and LV mass; PC3 vs. ECV.
Using IPA, we generated predicted functional pathways associ-
ated with validated mRNA targets of the miRNAs in each of these
PC groups (Fig. 2c–d). Top pathway hits included interleukin signal-
ing, PTEN signaling, and toll-like receptor signaling, with a strong
overall theme of inﬂammatory and ﬁbrotic pathways represented.
Furthermore, apoptosis and death receptor signaling were amongst
the signiﬁcant target pathways for PC2, the PC group associated
with LVEF. While there was some overlap in mRNA targets between
groups, a greater proportion of the mRNA targets identiﬁed were
unique to each PC group, suggesting that these represent clusters
of miRNA with distinct functionality that may contribute to the ob-
served CMR parameter correlations.
Finally, of the other exRNAs assessed in the 331 patients, the yRNA 1
fragment had a signiﬁcant correlation with change in LVMass, with a β
coefﬁcient of −0.043 and a Benjamini-Hochberg adjusted P value of
0.007. Here, a negative β coefﬁcient means greater increase in LVM
over time is associated with higher circulating yRNA 1 fragment
concentration.
3.2. Candidate miRNAs in Animal and Cell Models of MI
3.2.1. Temporal Regulation of Candidate miRNA in Animal Models
To determine the temporal regulation of exRNAs, candidate miRNAs
that were highly loaded on each PC and highly expressed were selected
for analysis in the murine I/R model. Time-points chosen were pre-
ischemic (baseline), acute to sub-acute phase (24 h and 1 week) and
chronic post-infarct phase (4 weeks). Both plasma and tissue had tem-
porally distinct expression of miRNA (Fig. 3; Table 3). At 24 h, miR-223-
3p and miR-30a-5p alone increased in plasma (Fig. 3a), while 13 of the
14 miRNA measured were upregulated in tissue (Fig. 3b; miR-100-5p,
miR-146a-5p, miR-150-5p, miR-146b-5p, miR-194-5p, miR-223-3p,
miR-29a-3p, miR-29c-3p, miR-30a-5p, miR-30d-5p, miR-378c, miR-
423-5p, miR-744-5p). Conversely, the majority of plasma changes
were seen at the chronic time-point (upregulation of miR-146a-5p,
miR-150-5p, miR-146b-5p, miR-21-5p, miR-29c-3p, miR-30a-5p, miR-
30d-5p, and miR-378c) with no signiﬁcant alterations in tissue miRNA
expression at this time. Fewer changes were observed at the sub-acute
(1 week) time-point: miR-21-5p increased in plasma and miR-194-5p,
miR-21-5p, and miR-423-5p were up-regulated in tissue. Notably,
miRNAs were not signiﬁcantly changed in plasma or tissue in sham-
treated animals (Fig. S1).
Fig. 1. (a) Box plot representing percentage of reads assigned to different RNA species from sequencing. (b) Flow chart describing experimental outline and analysis approach utilized in
this study.
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3.2.2. Cell Type Expression of miRNA and Hypoxia/Reoxygenation Model
We next assessed cell type sources of these miRNAs in dissociated
cells from adult wild type mice and found distinct clustering of
cardiomyocytes vs non-cardiomyocytes (Fig. 4a). Speciﬁcally, miR-
378c, and members of the miR-30 and miR-29 family were highly
expressed in cardiomyocytes compared to non-cardiomyocytess; miR-
423-5p, miR-21-5p, and miR-744-5p were highly expressed in ﬁbro-
blasts and endothelial cells; and miR-146b-5p, miR-150-5p, miR-223-
3p, and miR146a-5p had the highest expression in the non-
cardiomyocyte group (representing all non-cardiomyocyte cardiac
cells, including immune cells). Stimulation of expression and release
of miRNA by hypoxia/reoxygenation in cardiomyocytes was investi-
gated in NRVMs. miR-100-5p, miR-30d-5p, miR-21-5p, and miR-29b-
3p were up-regulated in EVs released in the media (Fig. 4b).
4. Discussion
In this study, we found that plasma circulating exRNA proﬁles that
include miRNAs and a YRNA fragment, are associated with post-MI
LVRm phenotypes. Interestingly, a murine model of MI showed that
Fig. 2. (a) Linear regression models for CMR parameters as a function of RNA PC score, *p b 0.05. (b) miRNA with loading N60 and detectable expression in N60% of samples for PC1-3
(numbers in brackets represent PC loading). (c) Venn diagram showing the overlap in the number of mRNA targets for miRNAs in each PC group. (d) Top 20 signiﬁcant pathways
from Ingenuity Pathway analysis for mRNA targets of miRNAs from PC1 (red), PC2 (blue), and PC3 (green).
Fig. 3. Heatmap of selected miRNAs in mouse plasma (a) and tissue (b) at baseline and following ischemia with 24 h, 1 week, and 4 weeks reperfusion (n = 5).
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the majority of our candidate miRNAs were not increased in plasma at
acute time-points and that temporal expression of miRNA differed in
tissue and plasma (results summarized in Table 3). Furthermore,
given the variety of cell types in the myocardium affected during
acute ischemic injury, we investigated whether expression of miRNAs
was cell-speciﬁc, uncovering that cells responsible for “myocardial”
miRNA expression are not exclusively cardiomyocytes. Nevertheless,
in studies of cardiomyocytes exposed to hypoxia/reoxygenation (a cel-
lular model of reperfused MI), we found several of our candidate
miRNAs released into the media and associated with extracellular vesi-
cles, suggesting that cardiomyocytes remain an important source of
non-coding RNA expression in response to injury and stress. Collec-
tively, these data add to a burgeoning literature on the post-MI molecu-
lar architecture and provide additional information on the complex
interplay between different cell types in orchestrating LVRm.
Due to their role in communication across cell types and organs,
miRNAs have been a rich source of investigation for novel biomarker
and mechanistic pathway discovery in CVD. Speciﬁcally, given their
dual role as ameasurable, circulating biomarker and function in gene si-
lencing in target cells (Creemers et al., 2012, Tijsen et al., 2010), exRNAs
have been proposed as mediators of early myocardial remodeling
(e.g., ﬁbrosis and hypertrophy) (Gao et al., 2017a), complementary to
natriuretic and other peptide-based biomarkers (Lee et al., 2006). In
this exploratory study, we show an association between different
groups of miRNAs with LVRm phenotypes by CMR (includingmeasures
related to myocardial extracellular matrix expansion and hypertrophy)
in the sub-acute post-MI phase.
It is important to note that the purpose of this studywas not to iden-
tify a deﬁnitivemarker for predicting the development of LVRm in post-
MI patients, but to better understand the associations of exRNA
Table 3
Summary of human, animal, and cell ﬁndings from this study for miRNA associated with PC groups.
RNAseq of
beneﬁcial
RT-qPCR validation Mouse model I/R In vitro Cell type
vs adverse remodelers
(n= 11 patients per
group)
(331 patients) LV tissue Plasma hypox/reox
(NRVMs)
Expression (Adult
wild-type mice)
Fold change P value PC1
(ΔLV)
PC2
(LVEF)
PC3
(ECV)
24 h 1 week 4
weeks
24 h 1 week 4
weeks
Media EVs Predominant cell type
miR-21-5p 1.96 0.13 X X 7.2**** 8.5* 16.3**** 10.3* FB/EC
miR-29a-3p 0.49 0.09 X 10.4*** FB/EC
miR-29b-3p 0.23 0.09 X 4.7* CM/EC
miR-29c-3p 0.24 0.05 X 374.1**** 52.8**** CM
miR-30a-5p 0.4 0.05 X X 162.0**** 20.2** 15.8* CM
miR-30d-5p 0.94 0.86 X X 92.3**** 10.8** 8.7* CM
miR-100-5p 0.4 0.09 X 9.0*** 6.7* CM/FB
miR-146a-5p 2.36 0.04 X 133.0**** 18.3*** Non-CM
miR-146b-5p 2.36 0.08 X 377.3**** 15.2* Non-CM
miR-150-5p 0.08 0.04 X 165.2**** 8.3 Non-CM
miR-194-5p 0.18 0.04 X 14.8**** 2.6* CM/non-CM
miR-223-3p 0.6 0.58 X 325.4*** 3.9** Non-CM
miR-378c 0.26 0.09 X 78.4**** 31.3** CM
miR-423-5p 0.91 0.85 X 9.7**** 4.3* FB/EC
miR-744-5p 2.11 0.06 X 169.2*** EC
In relation to poor remodellers (i.e. positive number = increased in poor remodeller).
Fold change vs baseline, *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001, Student's t-test.
Fig. 4. (a) Heatmap of candidate miRNAs in isolated murine cells. (b) Candidate EV-miRNAs released by neonatal rat ventricular myocytes into the media in response to hypoxia/
reoxygenation (2% oxygen for 24 h hypoxia followed by 12 h reoxygenation). Data represents mean ± SEM. *p b 0.05, Student's t-test.
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signatures with structural phenotypes (as assessed by CMR) in a well-
treated patient cohort, and garner insight into the biology driving differ-
ential LVRm. The patient group examined here received rapid revascu-
larization and optimal medical therapy resulting in a lack of extreme
LVRm phenotypes. Given the lack of sufﬁcient patients with adverse re-
modeling in this cohort (see Fig. S3), exRNA signatures perform simi-
larly to clinical models (that include age, gender, diabetes, NT-proBNP
and LV mass by CMR) and neither have sufﬁcient discrimination (AUC
range 0.54–0.59 range). Interestingly, when we measure exRNAs iden-
tiﬁed in this study in a population with chronic heart failure and a
wide range of LVRm by echocardiography, we can improve discrimina-
tion for remodeling over clinicalmodels (Shah et al., 2018). Future stud-
ies in larger cohorts of post-MI patients with a wider range of LVRm
would be needed to further develop these exRNA signatures as clinically
relevant biomarkers for prognostic use. Nonetheless, this study, which
includes the largest cohort of post-MI patients with detailed CMR phe-
notyping, demonstrated the association of exRNAs with speciﬁc fea-
tures of LVRm suggesting a possible role for exRNAs in molecular
processes implicated in LVRm.
We suggest that these groups of miRNAs may be functionally impli-
cated in cellular pathways relevant to LVRm, including apoptosis signal-
ing, immune cell function and signaling, and ﬁbrotic pathways
(demonstrated by IPA). Of interest is the relationship between each of
the principal components and the inﬂammatory signaling pathways.
Each PCA is related to NF-kB signaling which ultimately leads to in-
creased IL-1β activity. This pathway is of particular interest because of
the recent use of IL-1β pathway antagonist in clinical trials of post-MI
patients. The IL-1β receptor antagonist, anakinra, has been shown to re-
duce adverse post-MI LVRm, and decrease the risk of HF hospitalization
in a post-MI population (Abbate et al., 2013). Similarly, there are associ-
ations between each of the principal components and IL-6 signaling,
which is downstream of IL-1β activity. These ﬁndings underscore the
potential role of inﬂammation in post-MI remodeling, and are hypothe-
sis generating in regard towhether speciﬁcmiRNAs exert their effect on
post-MI remodeling through the IL-1β pathway, and whether dynamic
changes in these miRNAs in response to anti-inﬂammatory therapies
may serve as novel markers of response.
In this work we used an unbiased approach (RNAseq) on archived
post-MI plasma samples to demonstrate a wide array of RNAs in circu-
lation. In addition to miRNA, we identiﬁed several other exRNA species
(4 piRNAs, and 1 snoRNA) differentially expressed in individuals with
adverse vs beneﬁcial LVRm post-MI. Interestingly, a fragment of yRNA
1 was also differentially expressed in the RNAseq cohort (trending to-
wards statistical signiﬁcance, p = 0.15) and signiﬁcantly correlated
with change in LV mass in the RT-qPCR validation cohort, with higher
levels associated with adverse LVRm. A recent paper has described a
functional role for yRNA fragments that appears largely related to in-
ﬂammation; speciﬁcally, secretion of a 5′ fragment of yRNA 4 in EVs
from cardiosphere-derived cells and its cardioprotective role in a rat
model of I/R (Cambier et al., 2017). The present study is the ﬁrst to de-
scribe perturbation of yRNA fragment expression in human CVD. The
discovery of such non-coding RNAs highlights the importance of unbi-
ased approaches (e.g., deep RNAseq) for non-coding RNA and bio-
marker discovery in patient samples.
To further characterize exRNA candidates that were associated with
LVRm phenotypes, we utilized a mouse model of I/R to investigate the
temporal regulation of miRNA in plasma and tissue. Previous mouse
model studies have described a generalized increase in extracellular
RNA (not speciﬁc to microRNA) at 30 min and 2 h post permanent
LAD ligation (Stieger et al., 2017) and an increase in circulating
myocardium-associated miRNAs (miR-208a, miR-499, miR-1, and
miR-133) following 45 min ischemia and 3 h reperfusion (Chen et al.,
2014). While interesting, this likely reﬂects RNA released in response
tomyocardial damage similar to the release of troponins in the acute pe-
riod following MI. The current study aimed to evaluate miRNA across a
broader time period that assessed exRNA release in response to cellular
changes occurring in the acute, sub-acute, and chronic phases following
I/R. We observed distinct clustering of time-points by miRNA expres-
sion; baseline and acute (24 h) samples clustered distinctly in tissue,
whereas baseline and chronic (4 week) samples showed particularly
strong separation in plasma. Eleven of the 15 miRNA measured were
signiﬁcantly up-regulated in tissue at the 24 h time-point with only 3
up-regulated in plasma. During the sub-acute period (1 week) 3
miRNA were up-regulated in tissue and 2 in plasma, with one species
(miR-21-5p) up-regulated in both tissue and plasma. Finally, no
miRNAs were up-regulated in tissue at the chronic time point but 8 of
the miRNA candidates were up-regulated in plasma. Together, this
demonstrates a highly complex temporal regulation of post-MI miRNA
expression and suggests that when comparing data from different stud-
ies, the time-point atwhich sampleswere collected should be taken into
consideration.
The patient samples used in this study most closely align with the
sub-acute time-point (collected 2–4 weeks post-MI), however, it is dif-
ﬁcult to draw precise comparisons between the human and mouse
studies presented here. We have recently shown that plasma exRNAs
altered in human heart failure are concordantly regulated inmyocardial
tissue and plasma in a murinemodel of pressure-overload hypertrophy
and heart failure (Shah et al., 2018), suggesting the value of animal
models in derivation of mechanistic insights about exRNAs. Due to the
nature of murine I/R models, there is not signiﬁcant enough distinction
between animals to classify them as “beneﬁcial” or “adverse”
remodelers and thus it is difﬁcult to directly compare changes in expres-
sion in the mouse model vs the patient cohort (where differential ex-
pression was measured in beneﬁcial vs adverse remodelers). Instead,
we have compared post-MImiRNA expression levels to baseline expres-
sion levels in order to describe the temporal patterning of post-MI
miRNA expression.
The lack of correlation between tissue and plasma expression sug-
gests that either a signiﬁcant proportion of the miRNAs dysregulated
post-MI do not originate from cardiac tissue, or that there is a delay in
their release. Expression of our candidate miRNAs was cell-type speciﬁc
and miRNAs from each PC group were expressed across different cell
types, highlighting the importance of multiple cell types in the cardiac
remodeling processes. Interestingly, miRNA with high expression in
the “non-cardiomyocyte” cells included those previously associated
with inﬂammation and inﬂammatory cells (miR-146a-5p (Croci et al.,
2016, Feng et al., 2017), miR-146b-5p (Croci et al., 2016, Hulsmans
et al., 2012), and miR-150-5p (Croci et al., 2016)). While there are no
good cell culture models for LVRm, we did demonstrate that
cardiomyocytes release extracellular vesicle-associated miRNA in re-
sponse to hypoxia/reoxygenation in vitro, suggesting that stressors
can trigger the release of remodeling-associated exRNAs. Overall this
data suggests that multiple cell types contribute to the post-MI exRNA
milieu and that further studies will be required to determine the exact
reasons for the temporally distinct tissue and plasma expression
patterns.
The strengths of our study include the use of plasma small non-
coding RNAseq in a well-deﬁned population, unbiased initial measure-
ments, the availability of CMR measurements of LVRm, and the use of
animal and cellular models to interrogate temporal and cellular expres-
sion of RNA. Nevertheless, there are several limitations to our study that
merit comment. First, the size of the available discovery cohort limits
our ability to comprehensively identify more miRNA candidates. Sec-
ond, the “archival” nature of the samples utilized for RNAseq may
make them susceptible to RNA degradation, limiting RNA extraction
yield and our ability to comprehensively map and quantify known
RNAs. Indeed, several miRNA species detected from RNAseq data were
not expressed across all samples. Nonetheless, while we did identify a
panel of miRNA candidates from the discovery cohort that were differ-
entially expressed, we supplemented the panel with literature-curated
miRNAs to improve generalizability in the validation. Third, since the
start of the study, methodologies in bioﬂuids RNA isolation (Filant
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et al., 2018) and RNA sequencing platforms (Giraldez et al., 2017) have
advanced rapidly in the ﬁeld to decrease bias and improve the scope of
exRNA discovery. Finally, while the PCA-based approach allowed us to
take advantage of groups of similar RNAs to limit type 1 error in regres-
sion, we recognize that the effect size of the association between each
PC and each CMR parameter was modest. However, the general degree
of myocardial impairment post-MI (and its change over 6 months) was
itself modest in the individuals in this study (Fig. S3), limiting the ability
of regression techniques to “bring out” associations between miRNAs
and phenotypes. This nonetheless represents the current state of clinical
care in our center, and the population in which improved disease risk
stratiﬁcation is necessary.
Future studies utilizing fresh samples with careful phenotyping and
an unbiased screening method (next-generation sequencing) will be
necessary to validate the ﬁndings presented here. This is particularly
important for the consideration of any of these identiﬁed exRNAs as bio-
markers for the development of LVRm in post-MI patients, which will
require a much larger patient group. Furthermore, mechanistic studies
are required to determine the extent to which these candidates play a
functional role in the development of LVRm and to conﬁrm their in-
volvement in inﬂammatory pathways suggested by IPA.
In conclusion, this study has demonstrated that: 1) exRNA signa-
tures, are associated with CMR-deﬁned LVRm phenotypes; 2) plasma
and tissue levels of the candidate remodeling-associated miRNAs are
dynamically regulated in a murine model of I/R; and 3) distinct cell
types in the heart contribute to these miRNAs, pointing to the complex
intercellular interactions in the pathogenesis of LVRm. Overall, this data
adds to a growing literature that implicates plasma miRNAs as func-
tional mediators of cardiac remodeling processes and phenotypes.
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